Application of the Gyrolab microfluidic platform to measure picomolar affinity of a PD-L1-binding Adnectin™ radioligand for positron emission tomography
This case study demonstrates sub-nanomolar affinity determination anti-PD-L1 Adnectin to its ligand by scientists at Bristol Myers Squibb (BMS) using the Gyrolab XP with Affinity module multi-curve fitting software. The authors demonstrated advantages of the miniaturized Gyrolab immunoassay platform to perform thorough yet rapid assay development and measurement of in-solution affinity. Using Gyrolab, the authors were able to determine the affinity for the anti-PD-L1 Adnectin as 13 pM, which previously only had been estimated using SPR to be < 35 pM.
Cobra Biologics on the versatility of Gyrolab™ immunoassay platform in bioprocess development
Anna Lönnerbro is an Analytical Scientist at Cobra Biologics, a CMO and CRO of biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra Biologics offers support from small scale-up to large-scale bioprocess. Presenting at Gyrolab User Seminar in Copenhagen, Denmark on June 2, 2014, Anna described how the Gyrolab platform enables Cobra Biologics to deliver premium services with improved immunoassays.
How to get more reliable results with less effort
Analytical results that you can depend on are crucial to success, especially in a regulated environment. For example, immunoassays that consistently deliver reliable data with high accuracy and precision are worth their weight in gold. ELISA has been the standard for immunoassays, but this situation is changing. We present here two case studies that show how a move from ELISA to Gyrolab™ assays is helping your colleagues to improve their results and lab workflows.
Host-Cell Protein Analysis to Support Downstream Process Development
Sanofi scientists present the successful implementation of the Gyrolab immunoassay system as a reliable platform for high-throughput HCP analysis, in combination with a robotic liquid handling system. The results were comparable to their gold-standard ELISA method.
Combine DOE and Gyrolab system to quickly develop robust immunoassays
Two assay development teams at Pfizer have combined the systematic approach of DOE and the Gyrolab platform to streamline the development of robust immunoassays.
Validation and implementation of a pharmacokinetic assay on the Gyrolab™ platform for use in GLP toxicology study
Case study based on a poster by P. Verdier, A Choquart, N. Macé, and M-H Pascual, Biomarkers and Clinical Bioanalyses, Translational Medicine and Early Development, Sanofi, Paris, France. The poster was presented at the European Gyrolab Seminar in Paris, June 2017.
The challenging road to success: from ELISA to Gyrolab™ via MSD
Envigo were asked by a client to develop and validate a PK/TK assay for a monoclonal antibody used to treat cancer at levels as low as 10 ng/ml in cyno samples. The company first transferred the assay from ELISA to the MSD platform before finally transferring it to Gyrolab™ system, where the development and validation work was completed. Sarah Geen described the challenges encountered throughout this process and the strategies used to overcome them at the European Gyrolab Seminar in Amsterdam in June 2016.
One Mouse, One PK…the Magic of Capillary Microsampling and Gyrolab
Sufyan Maqbool is an Associate Scientist in Clinical Pharmacology and DMPK at MedImmune, in Cambridge, UK. His recent work has focused on developing capillary microsampling (CMS) methodologies for PK assays. On June 2, 2014 he presented his work at the Gyrolab User Seminar in Copenhagen, Denmark.